Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Immune Responses Evaluated for Tick-Borne Encephalitis

By LabMedica International staff writers
Posted on 13 May 2020
Tick-borne encephalitis (TBE) is an important vector-borne infection of the central nervous system (CNS). More...
The majority of all reported cases of TBE occur in adults. However, TBE should also be included in the differential diagnosis of pediatric CNS infections in endemic areas.

The chemokine CXCL13 is one of the key determinants of the humoral immune response at the site of an infection. CXCL13 is expressed in lymphoid organs and controls the recruitment and compartmentalization of B-cells and CD4+ T lymphocytes within these structures. CXCL13 is produced by microglia, stromal cells in the meninges, and infiltrating lymphoid cells.

Infectious disease specialists at the Medical University of Bialystok (Bialystok, Poland) analyzed anti-tick-borne encephalitis virus (TBEV) antibody levels, cerebrospinal fluid (CSF) and blood lymphoid populations, and concentrations of CXCL13 (a potent B-cell and T-cell chemoattractant), in 35 patients with TBE (20 adults and 15 children). TBE was defined as a febrile illness with signs of meningitis or meningoencephalitis, a CSF cell count of more than 5 cells/μL, and the presence of serum IgM and IgG antibodies to TBEV.

The detection of anti-TBEV IgG and IgM antibodies in serum and CSF was performed by enzyme-linked immunosorbent assay (ELISA), using SERION ELISA classic kits (Würzburg, Germany). The CXCL13 concentration quotient was calculated as QCXCL13 = CXCL13CSF/CXCL13serum. QCXCL13 was used as a measure of the chemical gradient of that chemokine. A value greater than 1 indicates a higher concentration of CXCL13 in the CSF than in the serum. All serum and CSF samples were stored at −80 °C until analysis of the chemokine. For flow cytometry, samples were analyzed within 18 hours on a FACSCanto II cytometer (BDBiosciences, San Jose, CA, USA). The Simultest IMK-Lymphocyte kit from BD Biosciences was used to study peripheral blood and CSF lymphocyte fractions

The scientists reported that when compared with the blood, the CSF lymphoid population was significantly enriched in CD4+ T-cells and relatively depleted in natural killer (NK) cells and B lymphocytes. In comparison with TBE meningitis, patients suffering from TBE meningoencephalitis (11, 31%) had a 3.5-fold higher median CSF CXCL13 concentration, 1.8-fold higher CSF/serum ratio of anti-TBEV IgG antibodies, and 1.8-fold higher median CSF cell count. CSF CXCL13 levels did not change significantly in children with TBE meningitis receiving supportive treatment, but decreased in children with TBE meningoencephalitis who received intravenous steroids.

The authors concluded that the CSF in patients with TBE was abundant in CD4+ cells and relatively depleted in NK cells and in B lymphocytes, when compared with the blood. A higher absolute number of lymphocytes in the CSF were associated with a more severe course of TBE. CXCL13 may be involved in the neuropathology of TBE by attracting different subsets of lymphocytes into the CSF, but it remains unclear whether this chemokine contributes directly to disease severity. The study was published on April 1, 2020 in the International Journal of Infectious Diseases.

Related Links:
Medical University of Bialystok
SERION
BDBiosciences



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.